- Home
- XOMA vs OBIO Comparison
XOMA vs OBIO Comparison
Compare XOMA & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMA
- OBIO
- Stock Information
- Founded
- XOMA 1981
- OBIO 2017
- Country
- XOMA United States
- OBIO United States
- Employees
- XOMA N/A
- OBIO N/A
- Industry
- XOMA Biotechnology: Pharmaceutical Preparations
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- XOMA Health Care
- OBIO Health Care
- Exchange
- XOMA Nasdaq
- OBIO Nasdaq
- Market Cap
- XOMA 320.8M
- OBIO 205.0M
- IPO Year
- XOMA N/A
- OBIO N/A
- Fundamental
- Price
- XOMA $28.59
- OBIO $5.83
- Analyst Decision
- XOMA Strong Buy
- OBIO Strong Buy
- Analyst Count
- XOMA 2
- OBIO 4
- Target Price
- XOMA $78.50
- OBIO $15.75
- AVG Volume (30 Days)
- XOMA 18.9K
- OBIO 44.2K
- Earning Date
- XOMA 11-05-2024
- OBIO 11-11-2024
- Dividend Yield
- XOMA N/A
- OBIO N/A
- EPS Growth
- XOMA N/A
- OBIO N/A
- EPS
- XOMA N/A
- OBIO N/A
- Revenue
- XOMA $15,239,000.00
- OBIO $2,079,000.00
- Revenue This Year
- XOMA $456.45
- OBIO $7.68
- Revenue Next Year
- XOMA $29.84
- OBIO $110.40
- P/E Ratio
- XOMA N/A
- OBIO N/A
- Revenue Growth
- XOMA 277.95
- OBIO N/A
- 52 Week Low
- XOMA $14.27
- OBIO $4.22
- 52 Week High
- XOMA $30.50
- OBIO $11.69
- Technical
- Relative Strength Index (RSI)
- XOMA 53.55
- OBIO 60.54
- Support Level
- XOMA $28.66
- OBIO $5.20
- Resistance Level
- XOMA $30.50
- OBIO $5.99
- Average True Range (ATR)
- XOMA 1.07
- OBIO 0.38
- MACD
- XOMA 0.21
- OBIO 0.12
- Stochastic Oscillator
- XOMA 55.56
- OBIO 87.20
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.